PMID- 16479977
OWN - NLM
STAT- MEDLINE
DCOM- 20060317
LR  - 20131121
IS  - 0485-1439 (Print)
IS  - 0485-1439 (Linking)
VI  - 47
IP  - 1
DP  - 2006 Jan
TI  - [Allogeneic stem cell transplantation with fludarabine/melphalan (non-TBI and 
      non-BU/CY) for patients aged 50 or more].
PG  - 9-15
AB  - Since 1999, we started to modify the conditioning regimen in allogeneic stem cell 
      transplantation for middle-aged to elderly patients (> = 50), and experimented 
      with 3 conditioning regimens. The clinical outcome was compared between 
      fludarabine/melphalan (FLU/MEL) conditioning and two other conditioning regimens 
      (reduced TBI (7.5 Gy) and BU/CY). From 1999 through 2005, a total of 33 patients 
      aged 50 or more with a hematological malignancy received allogeneic 
      transplantation in our institute. Seventeen received FLU/MEL conditioning and 16 
      received the other conditioning regimens. The FLU/MEL group included more 
      patients receiving unrelated bone marrow transplantation. There were no 
      differences in primary disease, risk, HLA disparity, GVHD prophylaxis and stem 
      cell source. Sustained engraftment was achieved in all evaluable patients in both 
      groups. Regimen-related toxicities were the same in both groups. 
      Transplant-related-mortality (TRM), relapse rate and disease-free survival were 
      22% and 25%, 25% and 47%, 59% and 37% in the FLU/MEL group and in the other 
      group, respectively. The incidence of grade II-IV acute GVHD was 25% and 13%, 
      respectively, and that of chronic GVHD was 38% and 56%, respectively. FLU/MEL 
      conditioning achieved satisfactory engraftment. Although the relapse rate showed 
      a lower tendency with FLU/MEL conditioning, there were no differences as far as 
      TRM was concerned. FLU/MEL conditioning could be a novel conditioning regimen for 
      middle-aged to elderly patients.
FAU - Inamoto, Yoshihiro
AU  - Inamoto Y
AD  - Department of Hematology, Japanese Red Cross Nagoya First Hospital.
FAU - Kuwatsuka, Yachiyo
AU  - Kuwatsuka Y
FAU - Tsujimura, Akane
AU  - Tsujimura A
FAU - Tokunaga, Masahiro
AU  - Tokunaga M
FAU - Oba, Taku
AU  - Oba T
FAU - Miyamura, Koichi
AU  - Miyamura K
FAU - Kodera, Yoshihisa
AU  - Kodera Y
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Rinsho Ketsueki
JT  - [Rinsho ketsueki] The Japanese journal of clinical hematology
JID - 2984782R
RN  - FA2DM6879K (Vidarabine)
RN  - P2K93U8740 (fludarabine)
RN  - Q41OR9510P (Melphalan)
SB  - IM
MH  - Disease-Free Survival
MH  - Female
MH  - Graft vs Host Disease/epidemiology
MH  - Hematologic Neoplasms/*therapy
MH  - Humans
MH  - Male
MH  - Melphalan/*therapeutic use
MH  - Middle Aged
MH  - *Stem Cell Transplantation/mortality
MH  - Transplantation Conditioning/*methods
MH  - Transplantation, Homologous
MH  - Vidarabine/*analogs & derivatives/therapeutic use
EDAT- 2006/02/17 09:00
MHDA- 2006/03/18 09:00
CRDT- 2006/02/17 09:00
PHST- 2006/02/17 09:00 [pubmed]
PHST- 2006/03/18 09:00 [medline]
PHST- 2006/02/17 09:00 [entrez]
PST - ppublish
SO  - Rinsho Ketsueki. 2006 Jan;47(1):9-15.